Nucleobase phosphonate analogs for antiviral treatment

Details Nucleobase phosphonate analogs for antiviral treatment Nucleobase phosphonate analogs for antiviral treatment

2004-07-30

2009-08-25

Berch, Mark L (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Phosphorus containing other than solely as part of an...

C544S244000, C544S243000

Reexamination Certificate

active

07579332

ABSTRACT:
The invention provides compounds with activity against infectious diseases. The compounds of the invention may inhibit retroviral reverse transcriptases and thus inhibit the replication, of the virus. The compounds of the invention may be useful for treating human patients infected with a human retrovirus, such as human immunodeficiency virus (strains of HIV-l or HIV-2) or human T-cell leukemia virus (HTLV-1 or HTLV-II) which results in acquired immunodeficiency syndrome (AIDS) and/or related diseases. Representative of the invention is a compound of the following formula, with the substituents defined herein:

REFERENCES:
patent: 4808716 (1989-02-01), Holy et al.
patent: 4968788 (1990-11-01), Farquhar
patent: 5013829 (1991-05-01), Nair et al.
patent: 5650510 (1997-07-01), Webb et al.
patent: 5663159 (1997-09-01), Starrett, Jr. et al.
patent: 5817647 (1998-10-01), Casara et al.
patent: 5854228 (1998-12-01), Martin et al.
patent: 5922696 (1999-07-01), Casara et al.
patent: 6018049 (2000-01-01), Hajima et al.
patent: 6127121 (2000-10-01), Meyer, Jr. et al.
patent: 6143877 (2000-11-01), Meyer et al.
patent: 2002/0103378 (2002-08-01), Ellis
patent: 2003/0004345 (2003-01-01), Casara et al.
patent: 2004/0014722 (2004-01-01), Babu et al.
patent: 0 269 947 (1988-06-01), None
patent: 0 532 423 (1993-03-01), None
patent: 0 618 214 (1994-10-01), None
patent: 0 701 562 (1997-06-01), None
patent: 07048374 (1995-02-01), None
patent: WO 91/19721 (1991-12-01), None
patent: WO 94/21604 (1994-09-01), None
patent: WO 94/22882 (1994-10-01), None
patent: WO 95/07920 (1995-03-01), None
patent: WO 96/15111 (1996-05-01), None
patent: WO 01/38584 (2001-05-01), None
patent: WO 03/087298 (2003-10-01), None
patent: WO 2005054269 (2005-06-01), None
Kim, et al., J. Med. Chem.; 1990; 33(4) pp. 1207-1213.
Carara et al, Bioorganic & Medicinal Chemistry Letters vol. 5, Issue 12, Jun. 22, 1995, pp. 1275-1280.
Zhang et al., European Journal of Inorganic Chemistry vol. 2003, Issue 13, Date: Jul. 2003, pp. 2426-2437 (Published Online: Jun. 24, 2003).
Julian-Ortiz et. at., J. Med. Chem. 1999, vol. 42, pp. 3308.
Olgilvie, Can. J. Chem. vol. 62, 1984, pp. 241-252.
Rosenberg, Collection of Czechoslovak Chemical Communications (1988), 53(11B), 2753-77.
Translation of JP 07048374A (1995).
Alexander et al. “Investigation of (Oxodioxolenyl)methyl Carbamates as Nonchiral Bioreversible Prodrug Moieties for Chiral Amines.” 39:480-486; J Med Chem, 1996.
Anan'eva et al. “(2-Iodoethyl)Phosphonic Derivatives.” 53(4):480-483; J. Gen. Chem. USSR, 1983.
Anderson et al. “2-Chloro-4(R),5(R)-dimethyl-2-oxo-1,3,2-dioxaphospholane, a New Chiral Derivatizing Agent.” 49:1304-1305; J Org Chem, 1984.
Asante-Appiah et al. “HIV-1 Integrase: Structural Organization, Conformational Changes, and Catalysis.” 52:351-363; Advances in Virus Research, 1999.
Bai et al. “Structural Specificity of Mucosal-Cell Transport and Metabolism of Peptide Drugs: Implication for Oral Peptide Drug Delivery.” 9:969-978: Pharm Res, 1992.
Barre-Sinoussi, Francoise “HIV as the cause of AIDS.” 348:31-35; Lancet, 1996.
Balsiger et al. “Synthesis of Potential Anticancer Agents. XVIII. Analogs of Carbamoyl Phosphate.” 24:434-436 ; J Org Chem, 1959.
Balthazor et al. “Nickel-Catalyzed Arbuzov Reaction: Mechanistic Observations.” 45:5425-5426; J Org Chem, 1980.
Benzaria et al. “Synthesis, In Vitro Antiviral Evaluation, and Stability Studies of Bis(S-acyl-2-thioethyl) Ester Derviatives of . . . ” 39:4958-4965; J Med Chem, 1996.
Beusen et al. “Solid-State Nuclear Magnetic Resonance Anlysis of the Conformation of an Inhibitor Bound to Thermolysin.” 38:2742-2747; J Med Chem, 1995.
Bhuta et al. “Analogs of Chloramphenicol: Circular Dichroism Spectra, Inhibition of Ribosomal Peptidyltransferase, and Possible Mechanis.” 23(12):1299-1305;J Med Chem, 1980.
Bundgaard et al. “Design and Application of Prodrugs.” pp. 113-191; Textbook of Drug Design and Development, 1991.
Burger et al. “Monoesters and Ester-amidates of Aromatic Phosphonic Acids.” 79:3575-3579; J Am Chem Soc, 1957.
Campagne et al. “(1H-Benzotriazol-1-yloxy)tris(dimethylamino)phosphonium Hexafluorophosphate-and . . . ” 60(16):5214-5223; J Org Chem, 1995.
Campagne et al. “Synthesis of Mixed Phosphonate Diester Analogues of Dipeptides Using BOP or P yBOP Reagents.” 34:6743-6744; Tet Lett, 1993.
Campbell et al. “The Synthesis of Phosphonate Esters, an Extension of the Mitsunobu Reaction.” 57:6331-6335; J Org Chem, 1992.
Casara et al. “Synthesis of Acid Stable 5′-O-Fluoromethyl Phosphonates of Nucleosides, Evaluation as Inhibitors of Reverse Transcriptase” 2:145-148; Bioorg Med Chem Lett, 1992.
Casteel et al. “Steric and Electronics Effects in the Aryl Phosphate to Arylphosphonate Rearrangement” 691-693; Synthesis , 1991.
Chen et al. “Design, Synthesis, and Biochemical Evaluation of Phosphonate and Phosphonamidate Analogs of Glutathionylspermidine . . . ” 40(23):3842-3850; J Med Chem, 1997.
Clayton et al. “BRL.8988 (Talampicillin), a Well-Absorbed Oral Form of Ampicillin.” 5(6):670-671; Antimicro Ag & Chemo, 1974.
Coe et al. “Synthesis of Some Mimics of Nucleoside Triphophates.” pp. 312-314; J. Chem. Soc. Chem. Commun., 1991.
Corey et al. “Selective Cleavage of Allyl Ethers Under Mild Conditions By Transition Metal Reagants.” 38(18):3224;J Org Chem., 1973.
Davies et al. “Dinucleotide Analogues as Inhibitors of Thymidine Kinase, Thyidylate Kinase, and Ribonucleotide Reductase.” 31(7) 1305-1308; J Med Chem, 1988.
De Clercq, Erick. “New Developments in the Chemotherapy of Lentivirus (Human Immunodeficiency Virus) Infections..” 724:438-456; Annals of the NY Acad of Sciences, 1994.
De Lombaert et al. “N-Phosphonomethyl Dipeptides and heir Phosphonate Prodrugs, a New Generation of Neutral Endopeptidase . . . ” 37:498-511; J Med Chem., 1994.
Efimov et al. “Synthesis of DNA Analogues with Novel Carboxamidomethyl Phosphonamide and Glycinamide Internucleoside Linkages.” 8:1013-1018; Bioorg Med Chem Lett., 1998.
Eliel et al. pp. 322-381; Stereochem Org Comp, 1994.
Esposito et al. “HIV Integrase Structures and Function.” 52:319-333; Advances in Virus Research, 1999.
Farquhar et al. “Biologically Reversible Phosphate-Protective Groups.” 72(3):324-325; J Pharm Sci., 1983.
Fasman et al., “Alkyl Bases, Nucleosides, and Nucleotides, UV Spectral Characteristic . . . ” pp. 385-394; Practical Handbook of Biochem and Molec Biol, 1989.
Frankel et al. “HIV-1 Fifteen Proteins and an RNA.” 67:1-25; Ann Rev Biochem, 1998.
Freeman et al. “3 Prodrug Design for Phosphantes and Phosphonates.” 34:112-147; Progress in Medicinal Chemistry, 1997.
Galeotti et al. “A Straightforward Synthesis of -Amino Phosphonate Monoesters Using BroP or TPyCIU.” 37(23):3997-3998; Tet Lett., 1996.
Griffin et al. “D-Glucopyranose 5-Deoxy-6-phosphonic Acid.” 78(10):2336-2338; J Am Chem Soc., 1956.
Hakimelahi et al., “Design, Synthesis, and Structure—Activity Relationship of Novel Dinucleotide Analogs As Agents Against Herpes . . . ” 38:4648-4659; J Med Chem., 1995.
Hottiger et al., “Human Immunodeficiency Virus Type 1 Reverse Transcriptase.” 377:97-120; Biol Chem., 1996.
Jacob III, Peyton “Resolution of ( )-5-Bromonomicotine. Synthesis of (R)- and (S)- Nornicotine of High Enantiomeric Purity.” 47:4165-4167; J Org Chem,, 1982.
Katz et al. “The Retroviral Enzymes.” 63:133-173; Ann Rev Biochem, 1994.
Khamnei et al,. “Neighboring Group Catalysis in the Design of Nucleotide Prodrugs.” 39:4109-4115; J Med Chem., 1996.
Khandazhinskaya et al. “Carbocyclic Dinucleoside Polyphosphonates: Interactions with HIV reverse Transcriptase and An

Affiliated with

Also associated with

Rating

Nucleobase phosphonate analogs for antiviral treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Nucleobase phosphonate analogs for antiviral treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleobase phosphonate analogs for antiviral treatment will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4092307